China’s Life Sciences and Healthcare-No.2 －The Good Vigilance Practice rule in China

China's Life Sciences and Healthcare-No.2 －The Good Vigilance Practice rule in China by Fumi Takatsuki and Yuchuan Sun　

I. China GVP
II. Applicable Entity
III. The Internal Pharmaceutical
IV. Internal Audits
V. Monitoring and Reporting Adverse

Authors： Fumi Takatsuki

OH-EBASHI and HANLING CHINA LEGAL NEWSLETTER 2022 July Issue


Publisher：Oh-Ebashi LPC & Partners & Hanling & Partners
Practice： Research and Development Marketing Regulation Cosmetics & Health/Beauty Care Products Chinese Practice
Date of publication： July 4, 2022

Other publications by Fumi Takatsuki

2024.09.26
Legal Affairs for Chinese Life Sciences and Healthcare No. 22: Shanghai Cosmetics Industry Advertising Compliance Guidelines
2024.01.24
Legal Affairs for Chinese Life Sciences and Healthcare No. 21: Revision to the Administrative Regulation on Wholesale, Retail, etc., of Pharmaceutical Products (Establishment of the Regulation on Supervision and Administration of Business Management and Quality of Pharmaceutical Products)
2023.11.28
Legal Affairs for Chinese Life Sciences and Healthcare No. 20: Notice on Enhancing the Supervision and Administration of Contract Manufacture of Drug Marketing Authorization Holders (No. 132 of 2023)
2023.10.27
Publication of the Draft Revisions to the Product Quality Law of China
2023.08.28
Obligation to Establish a Quality and Safety Management System in China
2023.07.25
Legal Affairs for Chinese Life Sciences and Healthcare No.19: Handling and Transborder Transfer of Human Genetic Resources and Information in Chinese Domestic Clinical Trials and Scientific Research
2023.05.24
Legal Affairs for Chinese Life Sciences and Healthcare No.18: Enactment of Regulations on Toothpaste in China
2023.03.28
Legal Affairs for Chinese Life Sciences and Healthcare No.17: Enforcement of the Rules for Responsible Supervision and Management of Quality and Safety Enforcement Entities for Drugs, Cosmetics and Medical Devices
2023.02.28
Legal Affairs for Chinese Life Sciences and Healthcare No.16: Rejection of UCB Pharma S.A. and GlaxoSmithKline (Ireland) Limited in the Extraterritorial Off-Site Inspection
2023.02.27
China’s Life Science and Healthcare-No.3 Amendment of the Regulations on Cosmetics in China
2023.01.20
Legal Affairs for Chinese Life Sciences and Healthcare No.15: System of the Person Responsible for the Production Safety (Safety Officer) of Food and Food-related Products in China
2022.11.29
Legal Affairs for Chinese Life Sciences and Healthcare (Part 14) -Chinese Regulations on Labeling and Advertisement for Cosmetics-
2022.10.25
Legal Affairs for Chinese Life Sciences and Healthcare (Part 13) -Chinese Regulations on Labeling and Advertisement for Cosmetics-
2022.07.14
Theory and Practice of Chinese Commercial Dispute Resolution（27）Consumer Contracts and Arbitration Clauses
2022.05.26
Legal Affairs for Chinese Life Sciences and Healthcare (Part 10) - Toward the Enforcement of the New Cosmetics GMP
2022.03.24
Legal Affairs for Chinese Life Sciences and Healthcare (Part 8) - Amendment to the Cosmetic Supervision and Administration Regulation for the First Time in 30 Years, and the Subsidiary Regulations on Administrative Measures for Cosmetic Registration, the Subsidiary Regulations on Administration Measures for Cosmetics Manufacture and Operation and the GMP for Cosmetics (3)
2022.03.14
A Legal Review of China’s Life Sciences and 2 Healthcare- No.1 －General Introduction and MAH System
2022.02.21
Legal Affairs for Chinese Life Sciences and Healthcare (Part 7) - Amendment to the Cosmetic Supervision and Administration Regulation for the First Time in 30 Years, and the Subsidiary Regulations on Administrative Measures for Cosmetic Registration, the Subsidiary Regulations on Administration Measures for Cosmetics Manufacture and Operation and the GMP for Cosmetics (2)
2022.01.25
Employment and Immigration Law Guide 2022　Jurisdiction:Japan
2022.01.21
Legal Affairs for Chinese Life Sciences and Healthcare (Part 5) - Amendment to the Cosmetic Supervision and Administration Regulation for the First Time in 30 Years, and the Subsidiary Regulations on Administrative Measures for Cosmetic Registration, the Subsidiary Regulations on Administration Measures for Cosmetics Manufacture and Operation and the GMP for Cosmetics (1)
2021.11.24
Legal Affairs for Chinese Life Sciences and Healthcare (Part 4) – Developments in Amendment of Regulations Concerning Wholesaling/Retailing of Pharmaceutical Products, Etc. (Measures on Supervision and Control of the Drug Business and Usage Quality (Draft for Comment))
2021.10.28
Legal Affairs for Chinese Life Sciences and Healthcare (Part 3) – Approaching the implementation of China GVP (Good Pharmacovigilance Practice) (effective from December 1, 2021) (2)
2021.09.30
Legal Affairs for Chinese Life Sciences and Healthcare (Part 2) –Approaching the implementation of China GVP (Good Pharmacovigilance Practice) (effective from December 1, 2021) (1)
2021.08.30
Legal Affairs for Chinese Life Sciences and Healthcare
2019.10.15
Points to Consider Regarding Advertising Expressions when Doing Business in China
2019.05.10
Case Study on Court Judgement in China Regarding Recognition and Enforcement of Foreign or External Arbitral Award
2018.12.10
Acts against Unjustifiable Advertisement and Misleading Representations in China
2018.04.24
Case Study on Court Judgment in China Regarding Recognition and Enforcement of Foreign Arbitral Award (14)
2017.12.27
100 Selected Cases in China, Series 250
2017.07.10
Office 40s: Business Legal Affairs: Theory and Practice regarding Civil and Commercial Laws in China [113]
2016.11.10
Recent Developments in Chinese Business Law, No. 50: Toward an Improved Cooling-off System
2016.08.15
100 Selected Cases in China, Series 234: A Case where the Court Recognized and Enforced an Award in a Foreign Arbitration between Chinese Domestic Companies Concerning Domestic Trade in China
2016.03.10
Latest Updates on Chinese Business Legal Affairs, 43rd Series: Draft Leniency Guidelines and Approval System Guidelines under the Antitrust Law of China
2016.03.10
Recent Developments in Chinese Business Law, No. 43: Draft Guidelines on the Leniency and Approval System under the Anti-monopoly Law of China
2015.11.15
100 Selected Cases in China, Series 225: A Case Involving the Copyrightable Nature of the Production of Match-up Games in an Online Battle Game
2015.08.10
Latest Updates on Chinese Business Legal Affairs, 36th Series: Ad-hoc Arbitrations and Relevant Practices in China
2015.05.13
Transcript of Lectures: Seminar on Issues concerning Arbitration Practices in China (2)
2015.04.14
Transcript of Lectures: Seminar on Issues concerning Arbitration Practices in China (1)
2015.02.12
Is an Agreement Requiring Arbitration In China by a Foreign Arbitration Body Valid?
2014.11.20
100 Selected Cases in China, 213th Series: A Case Involving the Liability of a Proprietor of an Online Shopping Mall for the Sale of Articles Infringing Trademark Rights
2014.11.19
Latest Updates on Chinese Business Legal Affairs, 29th Series: Current Risks of Non-Compliance in China and Penalties Therefor - GSK China's Commercial Bribery Case where a 53 Billion Yen Fine was Imposed
2014.03.10
Latest Updates on Chinese Business Legal Affairs, 22nd Series: Reformation of the Registered Capital System in China
2014.02.10
Collection of Claims and Information Disclosure by Courts in China
2013.08.10
Latest Updates on Chinese Business Legal Affairs, 15th Series: Latest Updates on the CIETAC Spin Off Issue
2013.03.15
100 Selected Cases in China, 193rd Series: The Case Dismissing Apple's Claim for Confirmation of the Attribution of Trademark Rights to the iPad
2012.11.10
Latest Updates on Chinese Business Legal Affairs, 8th Series: Promulgation of the Tertiary Guiding Cases Determined by the Supreme People's Court
2011.12.15
100 Selected Cases in China, 178th Series: The Case where the Judgment Upheld a Claim for Indemnification of Damages and Return of Unjust Enrichment concerning Abuse of Shareholders' Right
2011.06.15
Feature Article: On the Current Enforcement under the Antitrust Law in China - Practical Considerations on Antitrust Law in China
2010.12.15
Current Legal Risks and Considerations concerning Business in China as an Audit & Supervisory Board Member

MORE

Other publications about Research and Development

2023.08.24
Thematic-based: Legal Practice in the Healthcare Business
2022.07.04
China’s Life Sciences and Healthcare-No.2 －The Good Vigilance Practice rule in China
2022.03.14
A Legal Review of China’s Life Sciences and 2 Healthcare- No.1 －General Introduction and MAH System
2022.02.21
Legal Affairs for Chinese Life Sciences and Healthcare (Part 7) - Amendment to the Cosmetic Supervision and Administration Regulation for the First Time in 30 Years, and the Subsidiary Regulations on Administrative Measures for Cosmetic Registration, the Subsidiary Regulations on Administration Measures for Cosmetics Manufacture and Operation and the GMP for Cosmetics (2)
2022.01.21
Legal Affairs for Chinese Life Sciences and Healthcare (Part 5) - Amendment to the Cosmetic Supervision and Administration Regulation for the First Time in 30 Years, and the Subsidiary Regulations on Administrative Measures for Cosmetic Registration, the Subsidiary Regulations on Administration Measures for Cosmetics Manufacture and Operation and the GMP for Cosmetics (1)
2021.11.24
Legal Affairs for Chinese Life Sciences and Healthcare (Part 4) – Developments in Amendment of Regulations Concerning Wholesaling/Retailing of Pharmaceutical Products, Etc. (Measures on Supervision and Control of the Drug Business and Usage Quality (Draft for Comment))
2021.10.28
Legal Affairs for Chinese Life Sciences and Healthcare (Part 3) – Approaching the implementation of China GVP (Good Pharmacovigilance Practice) (effective from December 1, 2021) (2)
2021.09.30
Legal Affairs for Chinese Life Sciences and Healthcare (Part 2) –Approaching the implementation of China GVP (Good Pharmacovigilance Practice) (effective from December 1, 2021) (1)
2021.08.30
Legal Affairs for Chinese Life Sciences and Healthcare

MORE

Other publications about Chinese Practice

2024.09.26
[Report from China] How about a CASE like this?
2024.09.26
Legal Affairs for Chinese Life Sciences and Healthcare No. 22: Shanghai Cosmetics Industry Advertising Compliance Guidelines
2024.09.26
New Developments in the Cross-Border Transfer of Data in Free Trade Zones - Consideration of Cross-Border Transfer of Data in the Tianjin Free Trade Zone Data (Negative List) and Cross-Border Transfer of Data in the Shanghai Free Trade Zone (General Data List) with a focus on the Biomedical Sector
2024.07.24
[Report from China] Comparing Sino-Japanese Court Cases
2024.07.24
Brief Analysis of the Provisional Rules for the Prevention of Unfair Network Competition
2024.06.26
[Report from China] Were they all that precise?
2024.06.26
Chinese Corporate Law in the New Era and Its Impact on Foreign-Invested Enterprises – Part 5: Rights of Minority Shareholders under the Chinese Corporation Law
2024.05.24
[Report from China] Japanese Movies and TV Dramas in China
2024.05.24
Restructuring and Withdrawal of Chinese Subsidiaries (6)- Withdrawal (ii) Dissolution, Liquidation and Bankruptcy
2024.05.24
Chinese Corporate Law in the New Era and Its Impact on Foreign-Invested Enterprises – Part 4: Amendment to the Chinese Corporate Law and Liability of Management
2024.04.24
[Report from China] Transition to a Cash-friendly China
2024.04.24
Restructuring and Withdrawal of Chinese Subsidiaries (5)- Withdrawal (i) Share Assingment
2024.04.24
Chinese Corporate Law in the New Era and Its Impact on Foreign-Invested Enterprises – Part 3: Amendments to the Capitalization System of a Company
2024.04.10
Foreign Filling Restrictions of Major Countries －Mechanisms to Restrict Foreign Filing of Sensitive Inventions－
2024.03.22
[Report from China] Has Deflation Begun? Changing Consumption Styles in China
2024.03.22
Restructuring and Withdrawal of Chinese Subsidiaries (4) - Restructuring (iii) Company Split and Business Transfer
2024.03.22
Chinese Corporate Law in the New Era and Its Impact on Foreign-Invested Enterprises – Part 2: Revisions to the Design of Company Organizations
2024.02.22
[Report from China] Knowing China through Tea
2024.02.22
Restructuring and Withdrawal of Chinese Subsidiaries (3) - Restructuring (ii) Administration Services Company
2024.01.24
[Report from China] Miscellaneous Thoughts in My 12th Year of Living in Shanghai
2024.01.24
Restructuring and Withdrawal of Chinese Subsidiaries (2) - Restructuring (i) Merger
2024.01.24
Legal Affairs for Chinese Life Sciences and Healthcare No. 21: Revision to the Administrative Regulation on Wholesale, Retail, etc., of Pharmaceutical Products (Establishment of the Regulation on Supervision and Administration of Business Management and Quality of Pharmaceutical Products)
2024.01.24
Chinese Corporate Law in the New Era and Its Impact on Foreign-Invested Enterprises – Part 1: The First Major Revision Since 2005 and an Outline Thereof
2023.12.26
[Report from China] Marathons Familiar to the Chinese People
2023.12.26
Restructuring and Withdrawal of Chinese Subsidiaries (1) - Introduction
2023.11.28
[Report from China] Strategy for Eliminate Scalpers in China
2023.11.28
Legal Affairs for Chinese Life Sciences and Healthcare No. 20: Notice on Enhancing the Supervision and Administration of Contract Manufacture of Drug Marketing Authorization Holders (No. 132 of 2023)
2023.11.28
Response to the Risk of Misconduct in Business in China (5) - Changes in the Business Environment in China and Efforts to Maintain Business Health
2023.11.20
Inventions Made Across Boarders and the Attachment Foreign Filling Restrictions: Conflicts in the Restrictions and How They Are Handled
2023.10.27
[Report from China] It Depends on the Way of Presenting Statistics
2023.10.27
Publication of the Draft Revisions to the Product Quality Law of China
2023.09.29
[Report from China] Playing Golf in China
2023.09.29
Response to the Risk of Misconduct in Business in China(4) - Effect of Cross-border Data Regulations of China: Handling of Personal Information or the like in Internal Investigations
2023.08.28
[Report from China] Chinese Ventures with Great Commercial Enthusiasm
2023.08.28
Obligation to Establish a Quality and Safety Management System in China
2023.08.25
[Serial Article/Legal Affairs for Companies Expanding Overseas] [No.5] Security and Business: Conflict of Nations and Regulation of Certain Companies
2023.07.25
Legal Affairs for Chinese Life Sciences and Healthcare No.19: Handling and Transborder Transfer of Human Genetic Resources and Information in Chinese Domestic Clinical Trials and Scientific Research
2023.07.25
[Report from China] China’s University Entrance Examination System (Gaokao /National College Entrance Examination)
2023.05.24
[Report from China] Labor Day after the Zero-COVID Policy
2023.05.24
Legal Affairs for Chinese Life Sciences and Healthcare No.18: Enactment of Regulations on Toothpaste in China
2023.04.26
[Report from China] Chat GPT and China
2023.04.26
China Transborder Regulation of Personal Data (1)
2023.04.26
Response to the Risk of Misconduct in Business in China(3) - Establishment of an Internal Control System and Allocation of Management Resources in a Chinese Subsidiary
2023.03.28
[Report from China] Spring is the Season for Politics
2023.03.28
Legal Affairs for Chinese Life Sciences and Healthcare No.17: Enforcement of the Rules for Responsible Supervision and Management of Quality and Safety Enforcement Entities for Drugs, Cosmetics and Medical Devices
2023.03.28
Response to the Risk of Misconduct in Business in China(2) - Facilitating Information Sharing with Chinese Subsidiaries
2023.02.28
Response to the Risk of Misconduct in Business in China – Focusing on the Response to Signs of Misconduct
2023.02.28
Legal Affairs for Chinese Life Sciences and Healthcare No.16: Rejection of UCB Pharma S.A. and GlaxoSmithKline (Ireland) Limited in the Extraterritorial Off-Site Inspection
2023.02.28
A Commentary on the New Draft Amendment to the “Companies Law” of China – In Comparison with the First Draft Amendment
2023.02.27
China’s Life Science and Healthcare-No.3 Amendment of the Regulations on Cosmetics in China
2023.01.20
[Report from China] Traveling to China Immediately after the Lifting of the “Zero-Covid” Policy
2023.01.20
Legal Affairs for Chinese Life Sciences and Healthcare No.15: System of the Person Responsible for the Production Safety (Safety Officer) of Food and Food-related Products in China
2023.01.20
Labor Issues after Reclassification of the Novel Coronavirus Infectious Disease as a “Category B Infectious Disease Managed under Category B Protocols”
2022.12.28
[Report from China] Reversal of the Policies for the Novel Coronavirus Pandemic
2022.12.28
Labor Issues after Relaxation of the Policies for the Novel Coronavirus Pandemic
2022.11.29
[Report from China] My Experience When China’s Health Code System Indicated a Yellow Code
2022.10.25
[Report from China] The National Congress of the Communist Party of China and the National People’s Congress
2022.10.25
Legal Affairs for Chinese Life Sciences and Healthcare (Part 13) -Chinese Regulations on Labeling and Advertisement for Cosmetics-
2022.10.25
Review of the Draft Amendment to the “Company Act” in China - Revisions to Organizational Structure and the Impact on Japanese Companies -
2022.09.27
[Report from China] National Holidays in China
2022.09.27
Summary of the Amendment to the Chinese Anti-Monopoly Law (2) – Monopoly agreements and abuses of dominant market positions
2022.08.22
Summary of the Amendment to the Chinese Anti-Monopoly Law (1) – Combination of business operators
2022.08.22
[Report from China] Car License Plate Situation in Shanghai
2022.07.26
[Report from China] A Double Whammy with the Inflation and the Weak Yen
2022.07.26
Standard Agreement on the Extraterritorial Transfer of Personal Information
2022.07.04
China’s Life Sciences and Healthcare-No.2 －The Good Vigilance Practice rule in China
2022.07.04
Legal Compliance of Workplace Surveillance in China -From a Personal Information Protection Perspective
2022.06.23
[Report from China] Shanghai After the Lifting of the Lockdown
2022.05.26
[Report from China] Shanghai Lockdown to be Fully Lifted by Mid to Late June
2022.05.26
Legal Affairs for Chinese Life Sciences and Healthcare (Part 10) - Toward the Enforcement of the New Cosmetics GMP
2022.04.27
[Report from China] Lockdown in Shanghai Continues with No End in Sight
2022.04.27
Legal Affairs for Chinese Life Sciences and Healthcare (Part 9) - [Subsidiary Regulations on Administrative Measures for Monitoring of Adverse Reactions to Cosmetics] Overview
2022.04.27
Addressing Legal Issues Relating to the Resurgence of Covid-19 in China - Focusing on Treatment of Employees and Actions toward Trading Counterparties
2022.03.24
[Report from China] Latest on the Novel Coronavirus in China - Will the Government Change its Zero-Covid Policy?
2022.03.24
Legal Affairs for Chinese Life Sciences and Healthcare (Part 8) - Amendment to the Cosmetic Supervision and Administration Regulation for the First Time in 30 Years, and the Subsidiary Regulations on Administrative Measures for Cosmetic Registration, the Subsidiary Regulations on Administration Measures for Cosmetics Manufacture and Operation and the GMP for Cosmetics (3)
2022.03.24
Addressing the Bankruptcy or Liquidation Risk of Chinese Trading Counterparties - Key Points of Claim Collection Bearing in Mind the Risk of Corporate Bankruptcy
2022.03.14
A Legal Review of China’s Life Sciences and 2 Healthcare- No.1 －General Introduction and MAH System
2022.03.14
A Few Key Points of the China Personal Information Protection Law
2022.02.21
Legal Affairs for Chinese Life Sciences and Healthcare (Part 7) - Amendment to the Cosmetic Supervision and Administration Regulation for the First Time in 30 Years, and the Subsidiary Regulations on Administrative Measures for Cosmetic Registration, the Subsidiary Regulations on Administration Measures for Cosmetics Manufacture and Operation and the GMP for Cosmetics (2)
2022.02.21
[Report from China] Chinese New Year and Beijing Winter Olympic Games
2022.02.21
System and Legislative Framework Relating to Carbon Emission Trading in China
2022.01.21
[Report from China] Ten Years in Shanghai Saw Many Changes
2022.01.21
Legal Affairs for Chinese Life Sciences and Healthcare (Part 5) - Amendment to the Cosmetic Supervision and Administration Regulation for the First Time in 30 Years, and the Subsidiary Regulations on Administrative Measures for Cosmetic Registration, the Subsidiary Regulations on Administration Measures for Cosmetics Manufacture and Operation and the GMP for Cosmetics (1)
2022.01.21
Legal Affairs for Chinese Life Sciences and Healthcare (Part 6) - Trial Program for Cross-border E-commerce Retail Import of Drugs in Henan
2022.01.21
China’s Anti-foreign Sanctions Law and Points that Foreign Corporations should Note
2021.12.22
Personal Information Protection Law of China (2) – Processing of Personal Information and Consent by the Data Subject -
2021.12.22
[Report from China] Digital Yuan and Electronic Payment
2021.11.24
Legal Affairs for Chinese Life Sciences and Healthcare (Part 4) – Developments in Amendment of Regulations Concerning Wholesaling/Retailing of Pharmaceutical Products, Etc. (Measures on Supervision and Control of the Drug Business and Usage Quality (Draft for Comment))
2021.11.24
Measures on Security Assessment of Cross-Border Data Transfers (Draft for Comment) - Basic Points to Note -
2021.10.28
Legal Affairs for Chinese Life Sciences and Healthcare (Part 3) – Approaching the implementation of China GVP (Good Pharmacovigilance Practice) (effective from December 1, 2021) (2)
2021.10.28
Personal Information Protection Law of China (1) - Basic Points to Note -
2021.09.30
Legal Affairs for Chinese Life Sciences and Healthcare (Part 2) –Approaching the implementation of China GVP (Good Pharmacovigilance Practice) (effective from December 1, 2021) (1)
2021.09.30
Looking Back on the First 4 Years of the “Network Security Law” in China (Part II) -China's Regulations on Cross-border Transfer of Data, Etc.
2021.08.30
Looking Back on the First 4 Years of the “Network Security Law” (Part I)
2021.08.30
Legal Affairs for Chinese Life Sciences and Healthcare
2019.10.15
Points to Consider Regarding Advertising Expressions when Doing Business in China
2019.05.10
Case Study on Court Judgement in China Regarding Recognition and Enforcement of Foreign or External Arbitral Award
2019.03.22
Building a Compliance System for China-based Affiliates – Mainly on the Aspects of Transactions
2018.12.10
Acts against Unjustifiable Advertisement and Misleading Representations in China
2018.04.24
Case Study on Court Judgment in China Regarding Recognition and Enforcement of Foreign Arbitral Award (14)
2017.12.27
100 Selected Cases in China, Series 250
2017.02.01
Chinese Business Law System
2017.02.01
Chinese Business Law System: Organized by Internal Division and by Situation [Second Edition]
2016.12.01
Property Preservation in China - Provisions of the Supreme People's Court on several issues concerning the handling of property preservation cases by the people's court
2016.02.10
[Theory and Practice on Civil and Commercial Law in China (97)] Structure of Cross-Border E-Commerce with China and Legal Points to Note therein
2015.09.05
[Special Report] Risks Involved in Overseas Business Expansions of Small and Medium-Sized Enterprises, and Countermeasures Therefor _ Focusing on Legal Risks in China, Thailand, Vietnam and Indonesia -
2015.02.01
Supreme People's Court decision on Abuse of Market Dominant Position under China’s Antitrust Law
2014.10.01
Regulations and Countermeasures in Respect of Chinese Monopoly Agreements　-12 Japanese Auto Parts Suppliers are fined 20 Billion Yen
2014.06.01
100 Selected Cases in China (No. 208): An Introduction and Brief Study on the Notice of the Supreme People's Court of PRC on Publishing the Sixth Batch of Guiding Precedents.
2014.06.01
"(4) Part 1: Basic Legal System of lawsuits concerning Intellectual Property Rights in China" (co-authored)
2014.03.01
“Textbook on Chinese Legal Practice - From Entry to Withdrawal”
2013.06.01
Antitrust in the Emerging Economies of Asia: China and Indonesia
2013.05.01
Recent Amendments and Judicial Interpretation of Labor Related Regulations in China: Focusing on Amendments to the Labor Contract Law in China
2013.01.01
Outline and Practical Issues of Title Retention in Sales Contracts in China
2012.06.01
100 Selected Cases in China (No. 184): Case where the act of the managing company of a video-sharing site in providing data storage space to users who upload movies to such site was held to qualify as aiding copyright infringement
2011.10.01
China "Interim Provisions on Assessing the Impact of the Concentration of Business Operators on Competition"
2011.09.01
China "Interim Provisions on Assessing the Impact of the Concentration of Business Operators on Competition" (Draft for Public Comments)
2010.11.01
“The Roles that Banks Can Play in their Clients' Expansion in China”
2009.04.01
Global Intellectual Property Strategies for Companies Doing Business in China
2009.04.01
Withdrawal by Transfer of Equity Interest
2006.11.01
The Introduction of the Draft Antitrust Law of China and the Risk for Foreign Enterprises
2006.04.01
Guide to International Legal Practice (1) to (11)

MORE

Other publications about Cosmetics & Health/Beauty Care Products

2023.08.24
Thematic-based: Legal Practice in the Healthcare Business
2023.02.27
China’s Life Science and Healthcare-No.3 Amendment of the Regulations on Cosmetics in China
2023.01.20
Legal Affairs for Chinese Life Sciences and Healthcare No.15: System of the Person Responsible for the Production Safety (Safety Officer) of Food and Food-related Products in China
2022.07.04
China’s Life Sciences and Healthcare-No.2 －The Good Vigilance Practice rule in China
2022.05.26
Legal Affairs for Chinese Life Sciences and Healthcare (Part 10) - Toward the Enforcement of the New Cosmetics GMP
2022.04.27
Legal Affairs for Chinese Life Sciences and Healthcare (Part 9) - [Subsidiary Regulations on Administrative Measures for Monitoring of Adverse Reactions to Cosmetics] Overview
2022.03.24
Legal Affairs for Chinese Life Sciences and Healthcare (Part 8) - Amendment to the Cosmetic Supervision and Administration Regulation for the First Time in 30 Years, and the Subsidiary Regulations on Administrative Measures for Cosmetic Registration, the Subsidiary Regulations on Administration Measures for Cosmetics Manufacture and Operation and the GMP for Cosmetics (3)
2022.03.14
A Legal Review of China’s Life Sciences and 2 Healthcare- No.1 －General Introduction and MAH System
2022.02.21
Legal Affairs for Chinese Life Sciences and Healthcare (Part 7) - Amendment to the Cosmetic Supervision and Administration Regulation for the First Time in 30 Years, and the Subsidiary Regulations on Administrative Measures for Cosmetic Registration, the Subsidiary Regulations on Administration Measures for Cosmetics Manufacture and Operation and the GMP for Cosmetics (2)
2022.01.21
Legal Affairs for Chinese Life Sciences and Healthcare (Part 5) - Amendment to the Cosmetic Supervision and Administration Regulation for the First Time in 30 Years, and the Subsidiary Regulations on Administrative Measures for Cosmetic Registration, the Subsidiary Regulations on Administration Measures for Cosmetics Manufacture and Operation and the GMP for Cosmetics (1)
2021.11.24
Legal Affairs for Chinese Life Sciences and Healthcare (Part 4) – Developments in Amendment of Regulations Concerning Wholesaling/Retailing of Pharmaceutical Products, Etc. (Measures on Supervision and Control of the Drug Business and Usage Quality (Draft for Comment))
2021.10.28
Legal Affairs for Chinese Life Sciences and Healthcare (Part 3) – Approaching the implementation of China GVP (Good Pharmacovigilance Practice) (effective from December 1, 2021) (2)
2021.09.30
Legal Affairs for Chinese Life Sciences and Healthcare (Part 2) –Approaching the implementation of China GVP (Good Pharmacovigilance Practice) (effective from December 1, 2021) (1)
2021.08.30
Legal Affairs for Chinese Life Sciences and Healthcare

MORE

Other publications about Marketing Regulation

2024.01.24
Legal Affairs for Chinese Life Sciences and Healthcare No. 21: Revision to the Administrative Regulation on Wholesale, Retail, etc., of Pharmaceutical Products (Establishment of the Regulation on Supervision and Administration of Business Management and Quality of Pharmaceutical Products)
2023.11.28
Legal Affairs for Chinese Life Sciences and Healthcare No. 20: Notice on Enhancing the Supervision and Administration of Contract Manufacture of Drug Marketing Authorization Holders (No. 132 of 2023)
2023.08.24
Thematic-based: Legal Practice in the Healthcare Business
2022.07.04
China’s Life Sciences and Healthcare-No.2 －The Good Vigilance Practice rule in China
2022.05.26
Legal Affairs for Chinese Life Sciences and Healthcare (Part 10) - Toward the Enforcement of the New Cosmetics GMP
2022.03.24
Legal Affairs for Chinese Life Sciences and Healthcare (Part 8) - Amendment to the Cosmetic Supervision and Administration Regulation for the First Time in 30 Years, and the Subsidiary Regulations on Administrative Measures for Cosmetic Registration, the Subsidiary Regulations on Administration Measures for Cosmetics Manufacture and Operation and the GMP for Cosmetics (3)
2022.02.21
Legal Affairs for Chinese Life Sciences and Healthcare (Part 7) - Amendment to the Cosmetic Supervision and Administration Regulation for the First Time in 30 Years, and the Subsidiary Regulations on Administrative Measures for Cosmetic Registration, the Subsidiary Regulations on Administration Measures for Cosmetics Manufacture and Operation and the GMP for Cosmetics (2)
2022.01.21
Legal Affairs for Chinese Life Sciences and Healthcare (Part 5) - Amendment to the Cosmetic Supervision and Administration Regulation for the First Time in 30 Years, and the Subsidiary Regulations on Administrative Measures for Cosmetic Registration, the Subsidiary Regulations on Administration Measures for Cosmetics Manufacture and Operation and the GMP for Cosmetics (1)
2022.01.21
Legal Affairs for Chinese Life Sciences and Healthcare (Part 6) - Trial Program for Cross-border E-commerce Retail Import of Drugs in Henan
2021.11.24
Legal Affairs for Chinese Life Sciences and Healthcare (Part 4) – Developments in Amendment of Regulations Concerning Wholesaling/Retailing of Pharmaceutical Products, Etc. (Measures on Supervision and Control of the Drug Business and Usage Quality (Draft for Comment))
2021.10.28
Legal Affairs for Chinese Life Sciences and Healthcare (Part 3) – Approaching the implementation of China GVP (Good Pharmacovigilance Practice) (effective from December 1, 2021) (2)

MORE

Contact us

ページTOPへ